Apellis Pharmaceuticals shares plummeted on Friday after the European Medicines Agency (EMA) rejected its drug pegcetacoplan for treating geographic atrophy, a form of age-related macular degeneration. The EMA’s decision comes despite support from the European retina community and dissenting votes from some members of the committee.
The European Medicines Agency (EMA) has recommended a label update for Novo Nordisk’s Wegovy (semaglutide 2.4 mg), incorporating data showing its potential to reduce heart failure symptoms and improve physical function in obese individuals with heart failure with preserved ejection fraction (HFpEF). This update is based on positive results from the STEP HFpEF trials, which demonstrated Wegovy’s efficacy in reducing heart failure symptoms, improving physical limitations, and promoting weight loss compared to placebo.
